107 related articles for article (PubMed ID: 22943114)
1. Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases?
Vecsei L; Plangar I; Szalardy L
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):351-3. PubMed ID: 22943114
[No Abstract] [Full Text] [Related]
2. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
Schwarcz R; Pellicciari R
J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
[TBL] [Abstract][Full Text] [Related]
4. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
5. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.
Zádori D; Klivényi P; Vámos E; Fülöp F; Toldi J; Vécsei L
J Neural Transm (Vienna); 2009 Nov; 116(11):1403-9. PubMed ID: 19618107
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and function of brain kynurenines.
Schwarcz R
Biochem Soc Trans; 1993 Feb; 21(1):77-82. PubMed ID: 8449358
[No Abstract] [Full Text] [Related]
7. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
8. Basic mechanisms of kynurenine actions in the central nervous system.
Stone TW; MacGregor DG; Smith RA; Jones P; Behan WM; Graham DI
Adv Exp Med Biol; 1996; 398():195-201. PubMed ID: 8906266
[No Abstract] [Full Text] [Related]
9. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.
Pawlak D; Pawlak K; Malyszko J; Mysliwiec M; Buczko W
Int Urol Nephrol; 2001; 33(2):399-404. PubMed ID: 12092667
[TBL] [Abstract][Full Text] [Related]
10. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.
Stone TW
Prog Neurobiol; 2001 Jun; 64(2):185-218. PubMed ID: 11240212
[TBL] [Abstract][Full Text] [Related]
11. [Kynurenine and its metabolites in nervous system diseases].
Vécsei L; Schwab F
Orv Hetil; 1992 Jul; 133(29):1803-7. PubMed ID: 1386152
[TBL] [Abstract][Full Text] [Related]
12. Endogenous kynurenines as targets for drug discovery and development.
Stone TW; Darlington LG
Nat Rev Drug Discov; 2002 Aug; 1(8):609-20. PubMed ID: 12402501
[TBL] [Abstract][Full Text] [Related]
13. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
14. Production of quinolinic acid and kynurenic acid by human glioma.
Vezzani A; Gramsbergen JB; Speciale C; Schwarcz R
Adv Exp Med Biol; 1991; 294():691-5. PubMed ID: 1837700
[No Abstract] [Full Text] [Related]
15. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Guidetti P; Bates GP; Graham RK; Hayden MR; Leavitt BR; MacDonald ME; Slow EJ; Wheeler VC; Woodman B; Schwarcz R
Neurobiol Dis; 2006 Jul; 23(1):190-7. PubMed ID: 16697652
[TBL] [Abstract][Full Text] [Related]
16. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
Savitz J
Curr Top Behav Neurosci; 2017; 31():249-267. PubMed ID: 27221627
[TBL] [Abstract][Full Text] [Related]
17. Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice.
Larsson MK; Faka A; Bhat M; Imbeault S; Goiny M; Orhan F; Oliveros A; Ståhl S; Liu XC; Choi DS; Sandberg K; Engberg G; Schwieler L; Erhardt S
Neurochem Res; 2016 Sep; 41(9):2243-55. PubMed ID: 27165635
[TBL] [Abstract][Full Text] [Related]
18. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
19. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2010 Feb; 125(2):e40-5. PubMed ID: 19732942
[TBL] [Abstract][Full Text] [Related]
20. The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?
Joisten N; Ruas JL; Braidy N; Guillemin GJ; Zimmer P
Trends Mol Med; 2021 Oct; 27(10):946-954. PubMed ID: 34373202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
